Janet Macpherson, PhD
Senior Editor, ISCT Telegraft
Royal Prince Alfred Hospital
Australia
As 2026 bolts out of the blocks like a sprinter, the extremes of seasons (winter in Europe and summer in Australia) are tempered by the global perspective of the ISCT membership and Telegraft community and the desire to share for the benefit of the broad ISCT membership and CGT community. This month, the Editorial Board of the Telegraft is looking back at the content produced by ISCT members for our community in 2025. In this editorial, we highlight the top articles of the past year and celebrate our CGT community and the achievements we were honored to feature. Telegraft is published monthly and hosted on the ISCT website under the Telegraft Hub. Each issue includes an editorial and a mix of regular recurring contributed articles, one-off feature articles, contributions from our scientific, industry and regulatory sub-committees, and general information and promotion of ISCT opportunities and news from Industry. The Editorial board strives to provide a balance of content to support the needs of members across all pillars and sectors within the CGT field and in ISCT. The top read articles in 2025, like 2024, were penned by Telegraft editorial board members. As I near the completion of my term as senior editor, this is fantastic news! From the early days when we sent out content in PDF files, to a website that allows ISCT to measure impact, and the ability to periodically review what members are reading, as a board we strategize and include content that we believe is likely to be of interest to our readers throughout the year.
You (like me) might think that editorial articles receive more clicks and views because they are published more often. I don’t think this is the case. I do not have the full statistics, but the editorial team typically contributes 1 article per issue with around 10-12 other solicited articles coming from other authors. The frequency of inclusion does vary, with editorial content provided with every issue, while other recurring articles might be bi-monthly or less frequent.
I am pleased to share the top articles since December 2024 by author category, and invite you to catch up on any articles you might have missed by viewing the following the links:
From the Editors: Telegraft 2024: Celebrating a Year of Reflection, Inspiration and Innovation
From the Editors: Cell & Gene Therapy Approvals in 2024
From the Editors: Cell Therapy Regulation in 2025: A Turning Point for Global Innovation and Access
From the President’s Desk: The Three "Product" Problem of Cell and Gene Therapy
From the President’s Desk: The CGT Sector and End of the Year Candies for Children!
#ScientificSpotlight: In vivo CAR-T Therapy Challenges the Cancer Treatment Paradigm
#ScientificSpotlight: Under the microscope: Understanding Gamma Delta T cells
#IndustryMemberNews : Cryopreservation - Key Survey Findings from the ISCT Cold Chain Management & Logistics Working Group
#IndustryMemberNews: AI-enabled biomanufacturing innovation enhances affordability and access to cell and gene therapies
#RegulatoryWatchdog: SCA LRA Update - April 2025: Regulatory Landscape of Cell Therapies in Mexico
#CytotherapyCorner : ISCT, ARM, and ASGCT Issue Unified Joint Statement Calling for 10-year Global Moratorium on Heritable Human Genome Editing
#CytotherapyCorner: A Regulatory Roadmap for Cell and Gene Therapy Developers in Asia Pacific
#RegulatoryWatchdog: April 2025: Regulatory Landscape of Cell Therapies in Mexico
#RegulatoryWatchdog: NA LRA Watchdog - February 2025 - FDA’s Approval of Ryoncil: A Milestone for MSC Therapy or Just the Beginning?
#RegulatoryWatchdog: South and Central America LRA Watchdog Report - August 2025
#CommunityFeature: Level Up Your Career With Mentorship That Matters
#CommunityFeature: Singapore Cell and Gene Therapy Pan-Asia Summit (SCGT) 2025 In Partnership with ISCT: Igniting Momentum for Cell & Gene Therapies Across Asia
#RegionalandPartnerUpdates: ISCT 2025 Through Fresh Eyes: An Early-Stage Professional perception on Emerging therapies using MSCs
#TrainingandDevelopment: Announcing the 2025 ISCT Cell Therapy Leadership Training Program
On #IndustryMemberNews, throughout 2025 we have featured valuable content highlighting advances from our Industry members. I predict an uptake in content related to iPSCs in 2026 - here is a taster from 2025.
What this list may overlook is how central career development is to the Editorial Board’s mission. The Telegraft Editorial Board proudly includes ESP members on the committee, investing in the people who will drive the future of our industry.
Also, don’t forget that all financial ISCT members have access to the archive of Telegraft articles on the ISCT website under the Telegraft Hub.
As always, the Telegraft featured the work of our many ISCT committees and partners, such as FACT and JACIE. In the recurring Snapshot pieces, members of the Laboratory Practices Committee shared best practices around topics such as analytical testing validation. We also had members graciously cover important ISCT and FDA-sponsored webinars and news items, research, and discoveries from our outstanding ISCT members, and your Telegraft Editorial Board will be there to share it all!
P.S. If you would like to join the editorial board to shape Telegraft, please contact isct@isctglobal.org.